Business
Alzamend Neuro Issues Letter to Stockholders
Alzamend recently announced partnership with Massachusetts General Hospital for five phase II clinical trials of AL001, involving healthy human subjects and
About this update from Alzamend Neuro, Inc.
[{"type":"text","content":"\n\nAlzamend recently announced partnership with Massachusetts General Hospital for five phase II clinical trials of AL001, involving healthy human subjects and patients with Alzheimer’s, BD, MDD and PTSD\n\n\n\nAlzamend has executed an agreement to provide sufficient capital over the next 18 months to finance the initiation and progression of AL001 and ALZN002 clinical trials\n\n\n\n ATLANTA--(BUSINESS WIRE)--\nAlzamend Neuro, Inc. (Nasdaq: ALZN) (“Alzamend”), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer’s disease (“Alzheimer’s”), bipolar disorder (“BD”), major depressive disorder (“MDD”) and post-traumatic stress disorder (“PTSD”), today shared a letter from its Chief Executive Officer, Stephan Jackman.\n\n\nDear Stockholders,\n\n\nI am reaching out to share an update about our clinical programs and the outlook for the future.\n\n\nPlanned Clinical Trials\n\n\nThe heart of Alzamend’s mission lies in pioneering breakthroughs that have the potential to transform lives. I am thrilled to share that our planned clinical trials are currently on pace to make significant progress over the next year. The dedication of our research and development partners, in collaboration with experts in the field, has propelled us closer to potentially achieving significant milestones.\n\n\nAL001\n\n\nOur lead therapeutic drug candidate, AL001, is a novel lithium-delivery system that has the potential to deliver benefits of marketed lithium salts while mitigating or avoiding currently experienced toxicities associated with lithium. Our preclinical data for AL001 treatment showed prevention of cognitive deficits, depression and irritability in mice models, and has shown to be superior in improving associative learning, memory, and irritability, compared with lithium carbonate treatments. In March 2022, we announced that full data sets from our Phase I bioequivalent study affirmed that the extent of lithium absorption in plasma indicated that AL001 at 150 mg dosage is bioequivalent to the marketed 300 mg lithium carbonate product. In June 2023, we announced topline data from our Phase IIA multiple-ascending dose study in Alzheimer’s and healthy patients, which initiated in May 2022. Results from the Phase IIA study identified a maximum tolerated dose (“MTD”), as assessed by an independen...